Kola Mehmet, Hacioglu Dilek, Turk Adem, Erdol Hidayet
a Department of Ophthalmology, Faculty of Medicine , Karadeniz Technical University , Trabzon , Turkey.
Cutan Ocul Toxicol. 2016 Sep;35(3):185-9. doi: 10.3109/15569527.2015.1074586. Epub 2015 Aug 12.
To investigate the effectiveness and reliability of posterior sub-Tenon triamcinolone acetonide (PSTA) application in branch retinal vein occlusion (BRVO)-related macular edema.
Patients with confirmed BRVO-related macular edema were enrolled in the study. Patients were injected with a single, therapeutic dose of 40 mg PSTA. Detailed ophthalmic examination was performed at baseline and at 1, 3 and 6 months after the treatment. Best corrected visual acuity (BCVA), intraocular pressure (IOP), cataractogenic change (CC) and macular optical coherence tomography (OCT) analysis results were evaluated. The results were compared statistically.
Forty-one eyes of 41 patients with a mean age of 63.49 ± 10.99 (55-86) years, 15 (36.6%) females, were included in the study. BCVA in LogMAR values at 1 and 3 months were significantly better than at baseline, while no significant difference from baseline was observed in sixth month values (p < 0.001, p < 0.001 and p = 0.846, respectively). Central macular thickness values obtained using OCT were significantly lower at the first, third and sixth months compared to baseline (p < 0.001 for all). IOP elevation was determined in only two eyes (4.8%) at the end of the study period, and no CC was detected in any case.
PSTA application is an effective and safe option in BRVO-related macular edema.
探讨后Tenon囊下注射曲安奈德(PSTA)治疗视网膜分支静脉阻塞(BRVO)相关黄斑水肿的有效性和可靠性。
纳入确诊为BRVO相关黄斑水肿的患者。患者接受单次40mg PSTA治疗剂量的注射。在基线以及治疗后1、3和6个月进行详细的眼科检查。评估最佳矫正视力(BCVA)、眼压(IOP)、致白内障变化(CC)和黄斑光学相干断层扫描(OCT)分析结果。对结果进行统计学比较。
41例患者的41只眼纳入研究,平均年龄63.49±10.99(55 - 86)岁,女性15例(36.6%)。1个月和3个月时的LogMAR值表示的BCVA显著优于基线,而6个月时的值与基线无显著差异(分别为p < 0.001、p < 0.001和p = 0.846)。使用OCT获得的中心黄斑厚度值在第1、3和6个月时均显著低于基线(所有p < 0.001)。在研究期末仅2只眼(4.8%)出现眼压升高,且未发现任何致白内障变化。
PSTA注射是治疗BRVO相关黄斑水肿的一种有效且安全的选择。